



Attorney Docket No.: A013US

RECEIVED  
4/8/00  
C.E.  
TECH CENTER 1600/2000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of:

Examiner: VanderVegt, F.

Browning et al.

Group Art Unit: 1644

Serial No.: 09/299,139

Filing Date: April 23, 1999

For: SOLUBLE LYMPHOTOXIN-BETA RECEPTORS AND ANTI-  
LYMPHOTOXIN RECEPTOR AND LIGAND ANTIBODIES, AS THERAPEUTIC  
AGENTS FOR THE TREATMENT OF IMMUNOLOGICAL DISEASE

Certificate of Mailing by First Class Mail

I hereby certify that this correspondence is being mailed via United States First Class Mail to: Assistant Commissioner  
for Patents, Washington, D.C. 20231.

Date

August 7, 2000

Judith Herrick

*Judith A. Herrick*

RESPONSE

Assistant Commissioner for Patents

Washington, D.C. 20231

Dear Sir:

This amendment is responsive to the Office Action mailed on June 7, 2000, in connection with the above-identified application. This response is being filed with a petition for a one month extension of time for response and the appropriate fee under 37 C.F.R. section 1.1.7(c).

In response to the restriction requirement mailed on June 7, 2000, Applicants hereby elect to prosecute the claims of Group I, species (b) soluble LTBR and fusion protein thereof (claims 5-16, 23-27, 31-35), as described in the June 7, 2000 Office Action, paragraph 5, *with traverse*.

RECEIVED

AUG 22 2000

TECHNICAL 1600/2900

Applicants submit that each of the LTBR blocking agents listed in a-c of paragraph 5 are antagonists that disrupt or block the interaction that occurs between the ligand binding domain of LTBR and surface LT ligand. As such Applicants respectfully request that the 35 U.S.C.121 species election be removed.

Applicants expressly reserve the right to prosecute and obtain allowance of claims directed to Groups II, III, IV and V and the species in Group I, in divisional applications filed during the pendency of the present application.


In response to the Examiner's request for a paper copy and statement that the content of the CFR and paper are the same, please find enclosed a paper form of the Sequence Listing and a diskette containing a machine readable copy of the Sequence Listing. The undersigned hereby states that the contents of the Sequence Listing as filed in paper form are the same as the diskette. Please note that Applicants did not receive a Notice to Comply with Requirements For Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosure that was stated as being attached to the June 22, 2000 Office Action.

If the Examiner believes that a telephone conference would expedite the prosecution of this application, please call the undersigned at (617)-679-2079.

If the Patent Office determines that a further extension of time is required, Applicant hereby requests such extension and authorizes the Assistant Commissioner to charge the cost thereof to Deposit Account No. 02-2327.

Respectfully submitted,

Date: 8/7/00

  
Niki D. Cox, Esq.  
Reg. No. 42, 446  
BIOGEN, INC.  
14 Cambridge Center  
Cambridge, MA 02142  
(617) 679-2079 (Direct)  
(617) 679-2838 (Facsimile)